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Parkinson disease is a neurodegenerative disorder characterised by the cardinal symptoms of stiffness, 
resting tremor, slowness (bradykinesia) and reduction of movement (hypokinesia). Involvement 
of oxidative damage has been reported in the pathophysiology of Parkinson disease and its related 
complications. The purpose of this study was to examine the effect of daidzein to quench the free radicals 
produced as a result of the increased oxidative stress in Parkinson disease.Parkinson disease is induced 
by administration of reserpine (5 mg/kg/day, i.p) for 5 consecutive days. The symptoms of PD such as 
tremors, akinesia and rigidity were evaluated. The effect was evaluated by assessing various behavioral 
parameters (grip strength and locomotor activity), biochemical parameters (lipid peroxidation, and 
reduced glutathione), as well as histopathological parameters in brain tissue. Daidzein (an antioxidant) 
was administered at the dose of 50 and 100 mg/kg, p.o. once daily for 5 days. Reserpine significantly 
causes tremor, rigidity, akinesia and oxidative damage which were reversed by daily administration of 
daidzein when compared toreserpine group. There was a significant histological improvement in the 
neuronal degeneration in brain tissue with daidzein. So, the results indicated the protective effect of 
daidzein against PD.
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INTRODUCTION
Parkinson Disease is a disorder of the central 
nervous system, involving primarily a degeneration of 
certain nerve cells in the substantia nigra. PD is a slowly 
progressive neurodegenerative disease characterized by 
Pill rolling tremors, Akanthisia (inability to sit still), 
rigidity, resting tremor, kinesis (akinesia,dyskinesia), 
“freezing” and loss of postural reflexes, Instable 
(stooped) posture (Lorraine, Anthony, 2015). It is 
estimated that more than 1 percent of the population 
over age 65 are afflicted with Parkinson’s disease which 
can be increased with age (Pavan, Venkatraman, 2012).
Oxidative stress is thought to be the common underlying 
mechanism that leads to cellular dysfunction and demise. 
In Parkinson disease, oxidative stress induced by free 
radicals damages neuronal membrane lipids, proteins 
and other components of brain tissues and may cause 
dopaminergic degeneration in the substantia nigra 
(Jenner et al.; 1992). Antioxidant helps cells to cope with 
oxidative stress by effectively quenching free radicals. 
Antioxidants are generally regarded as safe – vitamin 
E, beta-carotene and lipoic acid (Gołembiowska et al.; 
2007). Daidzein is an isoflavone aglycone and an 
antioxidant that capable of stabilizing or deactivating free 
radicals before they attack cells (Xiaoping et al.; 2012). 
The study showed that daidzein is helpful in preventing 
breast cancer (Xiaoping et al.; 2012), osteoporosis 
(Ricciotti, Khaodhiar, Blackburn, 2005), and relief in 
menopause (Fonseca, Wendy, 2004).So,the objective 
of this study is to investigate the effects of daidzein in 
Parkinson disease induced by reserpine in rats.
MATERIAL AND METHOD
Animals
All experiments were performed on adult wistar 
rats weighing 150-250 g. The animals were procured 
from the Animal House, I.T.S College of Pharmacy 
Muradnagar, Ghaziabad. Animals were housed in group 
of 6 per cages, maintained at 23±2 °C; 55±5% humidity 
in a natural lightand dark cycle, with free access to food 
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and water. The experiments were performed during the 
light cycle in awake, freely moving animals that were 
adjusted to laboratory conditions before proceeding with 
the experiments. All animal procedures were approved 
by the ethical committee at our institution (CPCSEA 
registration number: 1044/PO/Re/S/07/CPCSEA) and 
performed in compliance with institutional guidelines for 
the care handling of experimental animals.
Experimental protocol
The animals were divided into eight groups of 
six rats. Daidzein was administered at a dose of 50 
and 100 mg/kg (Bayer, Colnot, Dekant, 2001). L-dopa 
+ carbidopa was administered at a dose of 30 mg/kg 
(Colpaert, 1987). Reserpine was given to all groups at the 
dose of 5 mg/kg i.p once in a day for 5 days consecutively. 
The drug treatment was given for 5 days and observations 
were made after 24 hours of the last treatment of reserpine. 
All the groups have undergone behavioral, biochemical 
and histopathological tests. The drugs were administered 
orally except group 2 and 3 which were given i.p and s.c 
route respectively (Vandanaet al.; 2015). An equivalent 
volume of CMC (Carboxy Methyl Cellulose) in saline 
was given to control groups. All the drugs were given in 
volumes of 10 mL/kg.
Parameter to be assessed
Induction of Parkinson disease by resepine
Reserpine, the antihypertensive agent induces 
depletion of central catecholamines stores. Injection of 
reserpine in rats causes hypokinesia, rigidity, and tremors. 
The animals were treated with reserpine (5 mg/kg, i.p., for 
5 consecutive days). After 24 h of last treatment animals 
was tested for induction of severity of tremors by giving 
the scores as follows: No tremors-0, occasional twitches-1, 
moderate or intermittent twitches-2, continues tremors-3. 
The number of tremors was counted for 5 min. If animals 
were not showing tremors then 0 score was be given, if 
animals showed 1 or 2 tremors then 1 score was given, 
animals showed 3 or 5 tremors in 5 min then 2 score 
was given and for 6 or more tremors, score was given 3. 
Akinesia was determined by holding the tail of animal and 
putting the front paws on the platform and let the animal to 
walk while holding (number of steps taken with forelimbs 
of animal was counted for 3 min) and muscular rigidity 
was determined by suspending the animal with forelimbs 
on middle part of horizontal glass rod (0.5 cm diameter) 
at the height of 25 cm above the table top and time to fall 
on the bottom surface was measured. The cut-off was 
kept for 1 min. The animals was treated with daidzein 
(50 &100 mg/kg, p.o.), or L-dopa-carbidopa (30 mg/kg, 
p.o.) 60 min before administration of reserpine for 5 
consecutive days (Colpaert, 1987; Vandana et al.; 2015).
Locomotor activity
After evaluation of tremors, akinesia, and muscular 
rigidity, locomotor activity was evaluated by using 
actophotometer. The apparatus consist of photoelectric 
cells, which are connected in circuit with a counter. When 
the beam of light falling on the photocell is cut off by the 
animal, a count was recorded for 10 min (Vandana et al., 
2015).
Rotarod activity
The latency to grip strength was evaluated by using 
rota rod apparatus. Each animal was placed on rotating rod 
(20 rpm) and latency to fall down was recorded in different 
groups of animals (Goel, Goel, Kumar, 2011).
Biochemical estimations
Dissection and homogenization: Animals were 
sacrificed by spinal dislocation immediately after 
behavioral assessments. The complete brain was removed 
and 10% (w / v-1) tissue homogenates were prepared 
in 0.1 M phosphate buffer (pH 7.4). Homogenate 
was centrifuged for 20 minutes at 15000 rpm and the 
supernatant was used for estimation of lipid peroxidation 
and reduced glutathione levels. 
Lipid peroxidation assay: The quantitative 
measurement of lipid peroxidation was perfomed 
according to the method of Ohkawa, Ohishi, Yagi, 1979. 
The amount of malondialdehyde (MDA) was measured 
by reaction with (TBA) thiobarbituric acid 535 nm using 
TABLE I – Experimental design
Group Treatment Dose mg/kg
1 Control (CMC in Saline) 10 mL/kg
2 Reserpine 5 mg/kg
3 Control (DMSO) 10 mL/kg
4 L-dopa + Carbidopa 100 mg/kg
5 Daidzein 50 mg/kg
6 Daidzein 100 mg/kg
7 L-dopa + Carbidopa + Daidzein 50 + 100 mg/kg
8 L-dopa + Carbidopa + Daidzein 100 + 100 mg/kg
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Shimadzu Spectrophotometer. The values were calculated 
using molar extinction coefficient of chromophore 
(1.56 × 10-6 m/cm/1) and expressed as n moles formed per 
mg of protein in the tissue.
Protein estimation
The protein content was measured according to the 
method of Lowry, Rosebrough, Farr, 1951, using bovine 
serum albumin as standard. Protein reacts with the folin’s 
ciocalteau phenol reagent to give colored complex. The 
color developed is due to reaction of alkaline copper with 
the protein and the reduction of phosphomolybdate by 
tyrosine and tryptophan present in the protein.
Estimation of reduced glutathione 
Reduced glutathione was estimated according to the 
method described by Ellman (1959). Rats was sacrificed 
by instant decapitation. The brains was quickly removed 
and washed with ice cold saline. 2mL of 10% homogenate, 
which was prepared in KCl solution, was taken and add 2.5 
mL of 0.02 M EDTA. Shake it vigorously. Take out 2mL 
of the above mixture and add 4mL of cold distilled water 
and 1 mL of 50% TCA and shake it for 10 minutes, later the 
content was transferred to centrifuged tube and centrifuged 
at 300 rpm for 15 min. Following centrifugation, 2 mL of 
the supernatant would be mixed with 4 mL of 0.4 M tris 
buffer (PH 8.9). The whole solution was mixed well and 
0.1 mL of 0.01 M DTNB was added, the absorbance was 
read with in 5 min of addition of DTNB at 412 nm against 
reagent blank with no homogenate. For blank readings, 
instead of 2 mL of homogenate 2 mL of distilled water 
was added. Results were calculated and expressed as micro 
moles (μmol) per gram of tissue weight.
Histological Examination: Samples of brain 
were stored in 10% formalin fixative solution, cut to 
4-µm thickness and stained by the Hematoxylin and 
Eosin. Sections were observed under light microscope 
(400×) for axonal degeneration and histopathological 
changes(Sudohet al.; 2004). Histopathological assessment 
was done at I.T.S Dental College Ghaziabad.
Statistical analysis
All the results are expressed as mean ± standard error 
mean (SEM) followed by analysis of variance (ANOVA) 
along with Dunnett’s ‘t’ test using SPSS software. The 
p<0.05 was considered to be statistically significant.
RESULTS
Effect of daidzein on Akinesia, tremor and 
muscular rigidity
Treatment with reserpine for 5 days produces 
tremors, and akinesia in animals. The intensity of numbers 
of tremors, and akinesia were significantly decreased 
by daidzein(50 and 100 mg/kg) carbidopa + levodopa 
(30 mg/kg) and combination of [(carbidopa + levodopa) 
and daidzein] significantly (p<0.01) as compared with 
control, reserpine and (carbidopa and levadopa) treated 
groups (Table II).
TABLE II - Effect of daidzein on muscular rigidity, tremors, akinesia in reserpine-induced motor defects
Group Treatment
Akinesia 





(duration of suspension 
in seconds)
1 Control (CMC in Saline) 38 ± 0.4 0 35 ± 0.3
2 reserpine (5 mg/kg) 18± 0.57a 4± 0.33 9 ± 0.2a
3 Control (DMSO) 37 ± 1.2a,b 0 12 ± 0.2a,b
4 L-dopa + carbidopa (100 mg/kg) 23± 0.86a 1± 0.22 32± 0.8a
5 daidzein (50 mg/kg) 25 ± 0.80a,b,c 2±0.33 16±0.7a,b,c
6 daidzein (100 mg/kg) 28± 0.7a,b,c 2± 0.21 25 ± 0.8a,b,c
7 L-dopa + carbidopa + daidzein (100 mg/kg + 50 mg/kg) 33 ± 0.1
a,b,c 1± 0.21 28± 0.6a,b,c
8 L-dopa + carbidopa + daidzein (100 mg/kg + 100 mg/kg) 35 ± 0.3
a,b,c 1± 0.16 32 ± 0.1a,b,c
All values were expressed as mean ±S.E.M (n=6), ap<0.001 when compared with control group, bP<0.01 when compared to reserpine 
and cP<0.001 when compared to carbidopa + levodopa (30 mg/kg) (ANOVA followed by Dunnett’s test).
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Effect of drug on Actophotometer and Rotarod
 
Treatment with reserpine for 5 days produces weak 
muscle strength in animals. Muscle strength significantly 
(p<0.01) increased by daidzein (50 mg/kg), daidzein 
(100 mg/kg). Carbidopa + levodopa (30 mg/kg), and 
combination of [carbidopa + levodopa and daidzein] 
and the locomotor activity is also increased significantly 
(p<0.01) with daidzein (50 mg/kg), daidzein (100 mg/kg). 
Carbidopa + levodopa (30 mg/kg), and combination of 
[carbidopa + levodopa and daidzein] when compared with 
the reserpine group (Table III).
Biochemical estimation
The lipid peroxidation levels and reduced glutathione 
levels significantly decreased and increased respectively 
with daidzein (50 mg/kg), daidzein (100 mg/kg). 
Carbidopa + levodopa (30 mg/kg), and combination of 
[carbidopa + levodopa and daidzein] as compared to 
reserpine and control group (Table IV)
Detection of neuronal death in sections stained 
with hematoxylin and eosin
Hematoxylin and eosin staining was used to estimate 
cell degeneration. Neuronal cells stained with H&E 
were quantified in the surface of the substantia nigra. 
Each midbrain section was viewed at low power (×10 
magnification) and the outlines of SNpc were determined. 
Histological assessment demonstrated that control groups 
rats showed normal SNpc neuronswhereas reserpine 
treated rats showed marked neuronal degeneration .The 
mean number of SNpc neurons was higher in control 
TABLE III - Effect of daidzein on locomotor activity, and grip strength in reserpine-induced motor defects
Group Treatment Locomotor activity (in 10 minutes)
Grip strength 
(latency to fall in seconds)
1 Control (CMC in Saline) 77.3 ± 1.8 31.5 ± 1.08
2 reserpine (5 mg/kg) 43.8 ± 4.1 17.3± 0.71
3 Control (DMSO) 66.3± 1.3 24.1± 0.98a,b
4 L-dopa + carbidopa (100 mg/kg) 49.6± 2.1a,b 19.8± 1.8a,b
5 daidzein (50 mg/kg) 54.5 ± 3.16a,c 21.1 ± 1.92,b
6 daidzein (10 0 mg/kg) 61.2 ± 2.54b,c 23.1 ± 1.88a,b,c
7 L-dopa + carbidopa + daidzein(10 0 mg/kg + 50 mg/kg) 65.5 ± 3.28
a,b 27.3 ± 1.17,b,c
8 L-dopa + carbidopa + daidzein(100 mg/kg + 100 mg/kg) 70.3± 2.39
a,b,c 29.6 ± 1.07a,b,c
All values were expressed as mean ±S.E.M.(n=6),aP<0.001 when compared with control group bP<0.01 when compared to reserpine 
cP<0.001 when compared to carbidopa + levodopa 30 mg/kg (ANOVA followed by Dunnett's 't' test).
TABLE IV - Effect of daidzein on biochemical parameters in brain tissue
Group Treatment TBARS  n mol (MDA/ mgProtein)
GSH 
(µmols / gm of tissue weight)
1 Control (CMC in Saline) 0.78±0.03 0.001±6.73
2 reserpine(5 mg/kg) 0.87±0.05 0.001±2.0
3 Control (DMSO) 0.64±0.02a 0.001±5.0a
4 L-dopa + carbidopa(100 mg/kg) 0.58±0.02a,b 0.0016± 4.7a
5 daidzein (50 mg/kg) 0.48±0.01a,b,c 0.0017±4.9a,b
6 daidzein (100 mg/kg) 0.46± 0.06a,b,c 0.0017± 5.4a,b,c
7 L-dopa + carbidopa + daidzein(100 mg/kg + 50 mg/kg) 0.44± 0.02
a,b,c 0.0018± 5.08a,b,c
8 L-dopa + carbidopa + daidzein(100 mg/kg + 100 mg/kg) 0.41± 0.02
a,b,c 0.0018± 5.80a,b,c
All values were expressed as mean ±S.E.M.(n=6), ap<0.01 when compared with control group; bp<0.01 when compared to reserpine; 
cP<0.01 when compared to carbidopa + levodopa (30 mg/kg ) (ANOVA followed by Dunnett’s test).
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group in comparison to reserpine group. Pharmacological 
treatment with daidzein (50 m/kg & 100 mg/kg), 
carbidopa + levodopa (30 mg/kg) alone or combined 
therapy showed higher percentage increases in number 
of SNpc dopaminergic neurons and less neuronal 
degeneration as compared to reserpine group (Figure1).
DISCUSSION
Parkinson Disease is a disorder of the central nervous 
system, involving primarily a degeneration of certain nerve 
cells in deep parts of the brain called the basal ganglia, and 
in particular a loss of nerve cells (or neurons) in a part of 
the brainstem called the substantia nigra (Reeve, Simcox, 
Turnbull, 2014). These cells make the neurochemical 
messenger dopamine, which is partly responsible for 
starting a circuit of messages that coordinate normal 
movement (Hélie, Paul, Ashby, 2012). Normally used 
antiparkinson drug for decreasing Parkinson activity such 
as carbidopa + levodopa. Therefore, this study conducted to 
evaluate and the effect of daidzein in Parkinson and to wide 
knowledge of mechanism involved in Parkinson disease. In 
FIGURE 1 - Histopathological evaluation of normal, reserpine and drug treated groups.
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this study, reserpine model are used to induce Parkinson in 
wistar rats. Reserpine induces muscular rigidity, tremors, 
and akinesia by depletion of central catecholamine storage 
(Vandana et al.; 2015). Daidzein (50 and 100 mg/kg, p.o.) 
and the combination of L-dopa and carbidopa with daidzein 
produced a significant reduction in these symptoms in rats.
Daidzein was also able to increase the locomotor 
activity and grip strength in rats. Reserpine induced 
motor defect was significantly reversed by daidzein. 
Amelioration of symptoms of reserpine by daidzein 
demonstrates anti-parkinsons activity.
Oxidative stress is one of the major reasons for 
nerve damage in many neurodegenerative disorders 
(Mosley et al.; 2006). In Parkinson’s disease, oxidation 
of dopamine by monoamine oxidase-B, and aldehyde 
dehydrogenase generates hydroxyl free radicals in the 
presence of ferrous ions (basal ganglia are rich in iron) 
(Subramaniam, Chesslet, 2013). The study showed that 
N-acetyl cysteine, an antioxidant has direct effect on the 
dopamine system of Parkinson patients (Monti et al.; 2016). 
Hence, to find out oxidative stress at various levels the 
defensive antioxidant enzymes in rat brain were measured. 
LPO is the measure of the excessive oxidation of the lipids 
in the body indicating increased superoxide production. 
Therefore, the oxidative stress indices were estimated in 
rat brain such as LPO and reduced GSH (Verma, Nehru, 
2009). The neuroprotective activity of the daidzein may 
be due to its antioxidant property, which reinforces 
antiparkinson activity of daidzein. In histopathological 
study substantia nigra showed neuronal degeneration 
(Carbidopa + Levodopa30 mg/kg + 50 mg/kg daidzein + 
5 mg/kg reserpine) & (100 mg/kg daidzein + 30 mg/kg 
carbidopa + levodopa + 5 mg/kg reserpine) showed better 
result with no swelling, it was show significant effect. The 
study showed that quercetin can reduce the neuronal death 
due to its antioxidant effect (El-Horany et al.; 2016).
So, the above behavioral and biochemical results 
suggest that daidzein has the ability to improve symptoms 
of Parkinsonism, in part, by the restoring the level of 
dopamine, and by the regulation of the antioxidant system. 
Thus, antioxidant and neuroprotective activities may be 
responsible for antiparkinsons effect. Hence, daidzein may 
be useful as a neuroprotective agent in the treatment of PD. 
CONCLUSION
Parkinson disease is a chronic, progressive, 
neurodegenerative disorder with multiple pharmacological 
treatments. The drugs employed clinically in treatment and 
management of Parkinson was associated with multiple 
other adverse effect which additionally make its treatment 
more difficult thus this research was aimed at examining 
daidzein in Parkinson and open new vistas in treatment 
and management of this disease.So, the results indicated 
the protective effect of daidzein against Parkinson disease 
induced by reserpine model test of wistar rats. The drug 
can therefore offer an alternative approach in parkinson 
state. Conclusively additional investigation is required on 
other animal models to obtain a dependable oversight of 
the outcome of daidzein on Parkinson in actual clinical 
scenario. 
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